Paper

4-(3-Alkyl-2-oxoimidazolidin-1-yl)-N-phenylbenzenesulfonamides as new antimitotic prodrugs activated by cytochrome P450 1A1 in breast cancer cells.

Published Oct 1, 2018 · Atziri Corin Chavez Alvarez, Mitra Zarifi Khosroshahi, M. Côté

Bioorganic & medicinal chemistry

Citations

Influential Citations

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

In Vitro Study

Study Snapshot

PAIB-SAs, a new class of cytochrome P450 1A1-activated prodrugs, show potential as potent antimitotics in breast cancer treatment by selectively activating CYP1A1-expressing cells.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

4-(3-Alkyl-2-oxoimidazolidin-1-yl)-N-phenylbenzenesulfonamides as new antimitotic prodrugs activated by cytochrome P450 1A1 in breast cancer cells.

References

Citations